205 related articles for article (PubMed ID: 15195929)
1. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.
Ishii KJ; Gursel I; Gursel M; Klinman DM
Curr Opin Mol Ther; 2004 Apr; 6(2):166-74. PubMed ID: 15195929
[TBL] [Abstract][Full Text] [Related]
2. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.
Wilson HL; Dar A; Napper SK; Marianela Lopez A; Babiuk LA; Mutwiri GK
Int Rev Immunol; 2006; 25(3-4):183-213. PubMed ID: 16818371
[TBL] [Abstract][Full Text] [Related]
3. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
Chaung HC
Int Immunopharmacol; 2006 Oct; 6(10):1586-96. PubMed ID: 16919831
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant activity of CpG oligodeoxynucleotides.
Klinman DM
Int Rev Immunol; 2006; 25(3-4):135-54. PubMed ID: 16818369
[TBL] [Abstract][Full Text] [Related]
5. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy.
Jahrsdörfer B; Weiner GJ
Curr Opin Investig Drugs; 2003 Jun; 4(6):686-90. PubMed ID: 12901226
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in immunostimulatory CpG oligonucleotides.
Rothenfusser S; Tuma E; Wagner M; Endres S; Hartmann G
Curr Opin Mol Ther; 2003 Apr; 5(2):98-106. PubMed ID: 12772497
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the development of immunostimulatory oligonucleotides.
Uhlmann E; Vollmer J
Curr Opin Drug Discov Devel; 2003 Mar; 6(2):204-17. PubMed ID: 12669456
[TBL] [Abstract][Full Text] [Related]
8. Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis.
Zeuner RA; Verthelyi D; Gursel M; Ishii KJ; Klinman DM
Arthritis Rheum; 2003 Jun; 48(6):1701-7. PubMed ID: 12794839
[TBL] [Abstract][Full Text] [Related]
9. Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides.
Klinman DM; Zeuner R; Yamada H; Gursel M; Currie D; Gursel I
Ann N Y Acad Sci; 2003 Dec; 1002():112-23. PubMed ID: 14751829
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of cationic lipid complexed with immunostimulatory DNA.
Rudginsky S; Siders W; Ingram L; Marshall J; Scheule R; Kaplan J
Mol Ther; 2001 Oct; 4(4):347-55. PubMed ID: 11592838
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
Schetter C; Vollmer J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
[TBL] [Abstract][Full Text] [Related]
12. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides.
Mutwiri GK; Nichani AK; Babiuk S; Babiuk LA
J Control Release; 2004 May; 97(1):1-17. PubMed ID: 15147800
[TBL] [Abstract][Full Text] [Related]
13. CpG motifs to modulate innate and adaptive immune responses.
Vollmer J
Int Rev Immunol; 2006; 25(3-4):125-34. PubMed ID: 16818368
[TBL] [Abstract][Full Text] [Related]
14. Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice.
Li Y; Kandimalla ER; Yu D; Agrawal S
Int Immunopharmacol; 2005 Jun; 5(6):981-91. PubMed ID: 15829414
[TBL] [Abstract][Full Text] [Related]
15. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy.
Mason KA; Ariga H; Neal R; Valdecanas D; Hunter N; Krieg AM; Whisnant JK; Milas L
Clin Cancer Res; 2005 Jan; 11(1):361-9. PubMed ID: 15671567
[TBL] [Abstract][Full Text] [Related]
16. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
17. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
Tewary P; Sukumaran B; Saxena S; Madhubala R
Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs.
Carpentier AF; Xie J; Mokhtari K; Delattre JY
Clin Cancer Res; 2000 Jun; 6(6):2469-73. PubMed ID: 10873101
[TBL] [Abstract][Full Text] [Related]
19. [Cancer immunotherapy with CpG-ODN].
Carpentier AF
Med Sci (Paris); 2005 Jan; 21(1):73-7. PubMed ID: 15639024
[TBL] [Abstract][Full Text] [Related]
20. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]